Atlas Trials

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Clinical trial NCT03222856 · COMPLETED

Trial details

NCT number
NCT03222856
Sponsor
MedSIR
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2017-12-14
Primary completion
2018-10-31
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.